Skip to content

A prediction study of antidepressant treatment effect on acute phase major depressive disorder based on neuroimaging features

A prediction study of antidepressant treatment effect on acute phase major depressive disorder based on neuroimaging features

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071218
Enrollment
Unknown
Registered
2023-05-08
Start date
2023-05-15
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder (MDD)

Interventions

SSRI group:N/A
SNRI group :N/A

Sponsors

Beijing Anding Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Out-patient, aged 16-65 years; No gender limit; The Han nationality; Right-handed; 2. Meet the diagnostic criteria for major depressive disorder of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), with either first episode or relapse, without psychotic symptoms; 3. No antidepressant therapy has been taken in the last 14 days of this depressive episode; 4. Primary school education or above, able to understand the content of the scale; 5. No contraindications to MRI scanning such as implantation of electronic and metal instruments; 6. Informed consent signed by the patient.

Exclusion criteria

Exclusion criteria: 1. Current or past DSM-5 compliant diagnoses other than depressive disorders include schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, neurodevelopmental disorders, neurocognitive disorders, disruptive impulse control, and conduct disorders; 2. Currently have substance-related and addictive disorders; 3. Serious organic diseases or history of important systems or organs; 4. Pregnant or lactating patients; 5. The researcher judged poor compliance or inappropriate participation.

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Scale (HAMD-17) total score reduction;Neuroimaging feature;

Secondary

MeasureTime frame
Correlation of neuroimaging features with depressive symptoms;Correlations between neuroimaging features and measures such as cognition / social functioning;

Countries

China

Contacts

Public ContactLiu Rui

Beijing Anding Hospital, Capital Medical University

liuruicomeon@163.com+86 15105179161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026